Chronic Neutrophilic Leukemia Complicated with Monoclonal Gammopathy of Undetermined Significance: A Case Report and Literature Review
Overview
Biotechnology
Pathology
Affiliations
Background: Study of the molecular biological characteristics of chronic neutrophilic leukemia complicated with plasma cell disorder (CNL-PCD) and lymphocytic proliferative disease (CNL-LPD).
Methods: The clinical data of a patient with chronic neutrophilic leukemia complicated with monoclonal gammopathy of undetermined significance (CNL-MGUS) in our hospital were reviewed, and the Chinese and/or English literature about CNL-PCD and CNL-LPD in PubMed and the Chinese database CNKI in the past 10 years was searched to analyze the molecular biological characteristics of this disease.
Results: A 73-year-old male had persistent leukocytosis for 18 months. The white blood cell count was 46.77 × 109/L and primarily composed of mature neutrophils; hemoglobin: 77 g/L; platelet count: 189 × 109/L. Serum immunofixation electrophoresis showed IgG-λ monoclonal M protein. A CT scan showed splenomegaly. Next-generation sequencing (NGS) showed that CSF3R T618I, ASXL1 and RUNX1 mutations were positive. It was diagnosed as CNL-MGUS. We summarized 10 cases of CNL-PCD and 1 case of CNL-LPD who underwent genetic mutation detection reported in the literature. The CSF3R mutational frequency (7/11, 63.6%) was lower than that of isolated CNL. The ASXL1 mutations were all positive (3/3), which may represent a poor prognostic factor. The SETBP1 mutation may promote the progression of CNL-PCD. We also found JAK2, RUNX1, NRAS, etc. in CNL-PCD.
Conclusions: Chronic neutrophilic leukemia may be more inclined to coexist with plasma cell disorder. The CSF3R mutation in CNL-PCD is still the most common mutated gene compared with isolated CNL. Mutations in SETBP1 and ASXL1 may be poor prognostic factors for CNL-PCD.
Deng Y, Han S, Gao X, Liu Y, Gao J Front Oncol. 2024; 14:1360791.
PMID: 38476370 PMC: 10928800. DOI: 10.3389/fonc.2024.1360791.
Research progress of additional pathogenic mutations in chronic neutrophilic leukemia.
Gao J, Han S, Deng B, Deng Y, Gao X Ann Hematol. 2023; 103(8):2591-2600.
PMID: 37993585 DOI: 10.1007/s00277-023-05550-6.
The impact of SETBP1 mutations in neurological diseases and cancer.
Kohyanagi N, Ohama T Genes Cells. 2023; 28(9):629-641.
PMID: 37489294 PMC: 11447826. DOI: 10.1111/gtc.13057.
Thomopoulos T, Symeonidis A, Kourakli A, Papageorgiou S, Pappa V Front Oncol. 2022; 12:891961.
PMID: 35494007 PMC: 9048254. DOI: 10.3389/fonc.2022.891961.
Gao J, Zhai L, Gao X, Min F J Clin Lab Anal. 2022; 36(4):e24287.
PMID: 35170077 PMC: 8993655. DOI: 10.1002/jcla.24287.